-transparent.png){kind=logo}
In the present study, we examined the regulation of neurotensin receptor following a chronic pharmacological blockade of the neurotensin transmission with a nonpeptide neurotensin receptor antagonist, SR 48692. Our results showed that treatment of the rats for five days with SR 48692, at a dose of 1 mg/kg, i.p., induced an increase of both the number of binding sites for 125I-neurotensin to whole brain membrane homogenates and neurotensin receptor mRNA levels in the ventral mesencephalon. This study brings the first evidence for an in vivo up-regulation of neurotensin receptors following their pharmacological blockade, and suggests that endogenous neurotensin exerts a tonic inhibitory control on neurotensin receptor mRNA levels.
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
June 1994,
British journal of pharmacology,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
April 1995,
British journal of pharmacology,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
May 2000,
Journal of neuroscience research,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
April 2001,
Neuroscience letters,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
November 1995,
Brain research. Molecular brain research,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
January 1995,
Peptides,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
January 1999,
Anticancer research,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
May 1995,
Molecular pharmacology,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
August 1996,
Brain research,
M Azzi, and
A Nicot, and
D Gully, and
P Kitabgi, and
A Bérod, and
W Rostène
June 1998,
The Journal of biological chemistry,
